The anti-obesity drug market comprises drugs that help in weight management and lowering body mass index in obese and overweight individuals. These drugs aid in reducing appetite, increasing feelings of fullness, and enhancing calorie burning. They are often prescribed as an add-on treatment to diet and exercise routines to lose weight and keep it off in the long run.
The Global anti-obesity drug market is estimated to be valued at US$ 2928.39 Mn in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the anti-obesity drug market are ARJO, Etac AB, Medline Industries Inc., Guldmann Inc., Sunrise Medical Inc., Stryker Corporation, Winncare Group (Mangar Health), Joerns Healthcare Inc., Invacare Corporation, Baxter (Hill Rom Holding Inc.), Gainsborough Healthcare Group, and Savaria Corporation (Handicare Group AB), among others. The growing prevalence of obesity due to sedentary lifestyles and consumption of junk food has fueled the demand for anti-obesity drugs in recent years. Moreover, several countries have achieved global expansion by obtaining regulatory approvals for novel anti-obesity drugs to curb the rising healthcare costs of obesity-related diseases.
Market key trends
In the Anti-Obesity Drug Market Size , there is a trend where pharmaceutical companies are increasingly developing gut hormone-based drugs to induce weight loss. These drugs help modulate appetite and food intake by targeting hormones like glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and oxyntomodulin that are released from the gut. Drugs mimicking the effects of these hormones have shown promising weight loss results with good tolerability. This innovative approach has opened up new avenues for effectively managing obesity.
Porter’s Analysis
Threat of new entrants: High costs of clinical trials and regulatory approval processes makes entry difficult.
Bargaining power of buyers: Large drug buyers like government entities and hospitals have significant negotiating power.
Bargaining power of suppliers: A few large pharmaceutical companies dominate the supply of new drug molecules.
Threat of new substitutes: Low threat as obesity treatments have few substitutes with comparable effectiveness and safety.
Competitive rivalry: High as major players compete on efficacy, safety profiles and cost of therapies.
The North American region accounted for the largest share of the anti-obesity drug market in 2024, due to the high obesity rate and availability of reimbursement for obesity treatment drugs and devices in the region.
The Asia Pacific region is expected to witness the fastest growth over the forecast period, owing to economic development, increasing obesity awareness, improving healthcare infrastructure and growing focus of global players in several Asia Pacific countries.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
